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1. Introduction
Lung diseases are among the leading causes 
of deaths worldwide. According to the 
World Health Organization[1] the chronic 
obstructive pulmonary disease (COPD) and 
lung cancer have even been rising from 
the fourth and ninth in 2000 to the third 
and sixth of most deadly disease in 2016, 
respectively. For treatment of lung diseases, 
direct application of the drug to the lung 
via aerosol inhalation is widely used due to 
its high therapeutic index, i.e., high efficacy 
at the site of disease and low side effects 
in secondary organs. Currently, inhalation 
therapy is a cornerstone for the treatment of 
pulmonary infections, asthma, COPD, and 
cystic fibrosis, but also treatment of lung 
cancer or even nonpulmonary disease such 
as diabetes is within reach.[2,3] Also nano-
technology enabled drugs (nanomedicines 
(NMs)) offer new diagnostic and therapeutic 
options for cancer and other diseases lever-
aging their unique features for controlled 
release, reduced drug toxi city, prolonged 
Targeted delivery of nanomedicine/nanoparticles (NM/NPs) to the site 
of disease (e.g., the tumor or lung injury) is of vital importance for improved 
therapeutic efficacy. Multimodal imaging platforms provide powerful tools 
for monitoring delivery and tissue distribution of drugs and NM/NPs. 
This study introduces a preclinical imaging platform combining X-ray (two 
modes) and fluorescence imaging (three modes) techniques for time-
resolved in vivo and spatially resolved ex vivo visualization of mouse lungs 
during pulmonary NP delivery. Liquid mixtures of iodine (contrast agent 
for X-ray) and/or (nano)particles (X-ray absorbing and/or fluorescent) are 
delivered to different regions of the lung via intratracheal instillation, nasal 
aspiration, and ventilator-assisted aerosol inhalation. It is demonstrated 
that in vivo propagation-based phase-contrast X-ray imaging elucidates 
the dynamic process of pulmonary NP delivery, while ex vivo fluorescence 
imaging (e.g., tissue-cleared light sheet fluorescence microscopy) reveals 
the quantitative 3D drug/particle distribution throughout the entire lung 
with cellular resolution. The novel and complementary information from 
this imaging platform unveils the dynamics and mechanisms of pulmonary 
NM/NP delivery and deposition for each of the delivery routes, which 
provides guidance on optimizing pulmonary delivery techniques and novel-
designed NM for targeting and efficacy.
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residence, and/or targeted delivery.[4–6] Consequently, numerous 
NM formulations are already in clinical use or are currently 
undergoing clinical trials.[7,8] In spite of this success a recent study 
reported that only about 0.7% of the applied dose of intravenously 
administered nanoparticles (NPs) accumulates at the tumor sites 
in animal models,[9] suggesting that targeting delivery of NM is 
still a major subject of both preclinical and clinical studies.
To better understand and optimize drug/NM delivery to the 
sites of disease within the lung, it is of central importance to 
quantitatively monitor the dynamic process of pulmonary drug 
delivery in the context of deposited dose, initial biodistribution, 
site-specific localization, biokinetics, and therapeutic efficacy 
(bioactivity) of NM. Noninvasive imaging techniques including 
magnetic resonance imaging (MRI), single photon emission 
computed tomography (SPECT), positron emission tomography 
(PET), photoacoustic (PA) imaging, ultrasound (US), X-ray-based 
imaging modalities (phase-contrast X-ray imaging (PCXI) and 
computed tomography (CT)), and optical imaging (e.g., in vivo 
imaging system (IVIS)) each provide different advantages in 
imaging drug/NM distribution, release, and efficacy.[10,11] MRI 
provides both morphological and functional information (e.g., 
target site of NM) in the human lung but is limited by poor 
spatial resolution (≈1 mm), slow image acquisition, and low 
sensitivity in the lungs of small animals.[12,13] Nuclear medical 
imaging including PET and SPECT offers high sensitivity, high 
imaging depth, and sufficient dosimetric accuracy for quantita-
tive biodistribution and biokinetics studies in the lung. Since 
those techniques often need a radiolabeled probe and suffer 
from poor spatial resolution and lack of anatomical information, 
hybrid imaging techniques have been proposed to overcome the 
latter limitations (e.g., joint use of SPECT-CT).[10] Taking advan-
tage of the combined spectral selectivity of molecular excitation 
by laser light and high resolution of ultrasound detection,[14] 
PA imaging is an emerging nondestructive hybrid technique 
(optics and acoustics) that allows deeper tissue visualization of 
fluorescent agents compared to optical imaging. Similar to US, 
PA can provide anatomical and dynamic imaging, but it is of 
limited use for the lung due to restricted ultrasound propaga-
tion.[15] Consequently, the penetration depth of light, sensitivity, 
and quantification ability offered by PA imaging are not suf-
ficient for determination of NM biodistribution and pharma-
codynamics in the lungs. X-ray-based approaches (PCXI and 
CT) have been recently applied to monitor the pulmonary fluid 
delivery dynamics and deposition[16–18] and lung pathophysiolog-
ical state[19] with high temporal and spatial resolution. The major 
challenges posed by X-ray modalities are that they are incapable 
of assessing NM bioactivity and for visualizing NM at cellular 
resolution. Leveraging the wide range of bioactive optical probes 
noninvasive optical imaging could resolve the bioactivity issue, 
but it suffers from poor spatial resolution and low dosimetric 
accuracy due to strong tissue scattering and absorption of light. 
There is no single imaging modality that allows for detection of 
the dynamics of pulmonary drug delivery, regional distribution 
profile, accurate dosimetry, and cellular localization of NM in 
intact organ/tissue of animal models.
Multimodal hybrid imaging techniques such as PET-CT 
and SPECT-MRI are increasingly used as they provide deeper 
insight into targeting and distribution profile of NM in terms 
of detection sensitivity, anatomical information, and spatially 
resolved dosimetry.[10,11,20] However, most studies have focused 
on determining the delivery and therapeutic efficacy of NM to 
xenograft tumor models in murine models,[21,22] while there is 
still a lack of understanding of pulmonary drug delivery. In spite 
of a large number of novel-designed NMs with enhanced phar-
macokinetic and pharmacodynamic properties,[7] such as non-
mucoadhesive particles (particles that do not adhere to mucus) 
prolonging lung retention for sustained release of drugs in the 
lung,[23] monitoring the controlled pulmonary delivery of NM 
in real-time with subsequent analysis of regional spatial distri-
bution, accurate dosimetry, and cellular localization of NM in 
the lung is still a major unmet need.
This study therefore aims to decipher the dynamics of pul-
monary delivery of NPs as well as their regional distribution, 
dosimetry, and cellular localization by multimodal imaging 
leveraging X-ray and fluorescence-based imaging techniques. 
Lung tissue usually produces low contrast in conventional 
X-ray images, but the visibility of the lungs can be enhanced 
using phase-contrast techniques that exploit the phase shift 
introduced by a sample. For weakly absorbing materials such 
as soft tissue and air, the difference in the phase shift is sig-
nificant, which leads to contrast enhancement. Propagation-
based phase-contrast X-ray imaging (PB-PCXI) was chosen here 
since this technique requires only a single exposure (compared 
to, e.g., grating-based phase-contrast imaging), so it is ideal for 
imaging dynamic processes.[24] Furthermore, it is a simple tech-
nique, because the only change with respect to conventional 
absorption imaging is an increased sample-to-detector distance 
and increased source coherence. This coherence requirement 
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usually limits the use of PB-PCXI to synchrotron facilities.[25] 
In this study the Munich Compact Light Source (MuCLS) was 
used to produce a sufficiently coherent X-ray beam to obtain 
edge-enhanced images via PB-PCXI. The acquired images 
include attenuation and phase information, with the attenua-
tion effects rendering the bones and highly absorbing contrast 
agents visible, and the phase effects rendering the lungs and 
airways visible.[26] Here, PB-PCXI was applied to the in vivo 
real-time monitoring of controlled NP-liquid delivery to dif-
ferent regions of the lung, and subsequent ex vivo CT and fluo-
rescence imaging (here epifluorescence imaging of the whole 
or dried-sliced lung or tissue-cleared light sheet fluorescence 
microscopy (LSFM)[27]) further provided the 3D NP distribution 
profile throughout the entire lung in both a qualitative and a 
quantitative manner. The advantages and limitations of each of 
these techniques are discussed and we demonstrate the poten-
tial of this multimodal imaging platform for resolving mecha-
nisms of pulmonary drug delivery and specific features of the 
NP distribution profile observed for three of the most widely 
used preclinical modes of pulmonary application, namely, 
intratracheal instillation, ventilator-assisted aerosol inhalation, 
and nasal aspiration.
2. Results
The multimodal imaging approaches presented here provide 
unprecedented concomitant insights into dose, distribution, 
and mechanism of pulmonary delivery of drugs at high tem-
poral and spatial resolution. In vivo PB-PCXI allows for non-
invasive time-resolved monitoring of the dynamic process 
of drug/nanoparticle delivery, while fluorescence-based ex 
vivo imaging (IVIS and tissue-cleared LSFM) offers quanti-
tative dosimetry and accurate 3D localization of fluorescent 
tracers (here NPs) with cellular resolution at one time point. 
Each of these methods requires the presence of either X-ray 
contrast agents or fluoroactive substances. Here a variety of 
NPs and molecular substances are used, including the clini-
cally approved iodine as well as gold NPs, iron oxide particles, 
quantum dots (QDs) for X-ray imaging, as well as QDs and 
polystyrene-SkyBlue and melamine resin NPs for fluores-
cence-based imaging (Table 1). Except for QDs, which are both 
X-ray absorbing and fluorescent, all other substances require 
co-application of two contrast agents. The insoluble particles 
used here have a diameter between 18 and 900 nm with a rela-
tively narrow size distribution (geometric standard deviation 
< 1.4; Figure S1, Supporting Information).
A schematic overview of the various imaging modalities is 
presented in Figure 1. During the pulmonary delivery process 
time-resolved in vivo PB-PCXI was performed and mice were 
sacrificed immediately after completion of delivery, lungs were 
perfused (removal of blood), and then excised. Subsequent ex 
vivo imaging was performed on the very same lungs using 
either LSFM on tissue-cleared lungs or X-ray imaging (CT scan) 
followed by two IVIS fluorescence imaging modalities on dried 
lungs, namely, whole lung fluorescence imaging (WLFI) and 
lung slice fluorescence imaging (LSFI).
2.1. Time-Resolved In Vivo Monitoring of Controlled Pulmonary 
NP Delivery with PB-PCXI
For analysis of the mechanisms involved in pulmonary drug 
delivery (here: iodine-NP) the temporal evolution of drug accu-
mulation in the different regions of the lung was monitored 
for various forms of drug application in real time by PB-PCXI. 
The intratracheal instillation and X-ray imaging setup is 
depicted in Figure 1a. As described by Gradl et al.,[24] mice 
were fixed in an upright position, mechanically ventilated, 
and an iodine-polystyrene NP suspension was instilled slowly 
into the lungs using a remotely controlled syringe pump. 
This permits delivery of a known amount of liquid at a con-
trollable and constant rate (here 4.2 µL s−1, i.e., 100 µL within 
24 s). Triggered by the ventilator, one image per breath was 
captured during an end-inspiratory breath-hold phase, which 
minimizes inflation/deflation-induced blurring effects.[24] This 
allowed for time-resolved visualization of the pulmonary NP 
delivery process. Since intratracheal instillation is typically 
Small 2019, 1904112
Table 1. Main characteristics and hence complementarity of the propagation-based phase contrast X-ray imaging (PB-PCXI), computed tomography 
(CT), whole lung fluorescence imaging (WLFI), lung slice fluorescence imaging (LSFI), and light sheet fluorescence microscopy (LSFM) at a glance. 
Strengths are graded low (+) to high (+++).
Imaging method In vivo/ex vivo Dimension Resolution Fidelity Anatomical 
information
Dosimetry Technical 
complexity
Contrast agents
PB-PCXI In vivo 2D + time + +++ + ++ +++ IodineM1, iron 
oxide particlesM2, 
gold NPs, QDs
CT Ex vivo 3D ++ +++ ++ + ++
WLFI Ex vivo <2Da) + ++ + ++ + SkyBlue NPsM1, 
melamine NPsM1,2, 
quantum dots
LSFI Ex vivo 2D/3D + ++ ++ +++ ++
LSFM Ex vivo 2D/3D +++ ++ +++ +++ ++
M1: mixture 1 (iodine + SkyBlue NPs/melamine NPs); M2: mixture 2 (iron oxide + melamine NPs). a)Penetration depth is ≈1 mm (depending on wavelength)—only 
fraction of murine lung is imaged.
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performed by rapid manual emptying of a syringe (within less 
than 1 s), we thus refer to the instillation process used here as 
“slow-instillation.”
Figure 2a shows the X-ray images obtained with this setup. 
The rib cage and spinal cord of the mouse (dark structures) 
as well as the lung (bright area within the rib cage) enclosing 
Small 2019, 1904112
Figure 1. Schematic workflow of multimodal imaging platform from in vivo propagation-based phase contrast X-ray imaging (PB-PCXI) to either ex vivo 
light sheet fluorescence microscopy (LSFM) or ex vivo lung slice fluorescence imaging (LSFI). Those imaging processes involved in the data acquisi-
tion (in vivo PB-PCXI a); ex vivo computed tomography (CT), ex vivo whole lung fluorescence imaging (WLFI) and LSFI b); and ex vivo LSFM c)) and 
sample processing (in situ lung perfusion (a), ex vivo lung drying and inflation (b), and ex vivo lung tissue clearing (c)) were applied in this study.
Figure 2. Controlled iodine-nanoparticle liquid delivery to the left/right or whole lung via slow-instillation can be visualized in vivo using PB-PCXI. 
a) A raw X-ray image directly captured during instillation of 100 µL iodine-polystyrene NP liquid to the mouse lung. b) Same as panel (a), but a pre-
delivery image is subtracted, clearly enhancing the visibility of the iodine-polystyrene NP liquid in the left half of the lung. c–e) Difference images as 
well, but for different experiments delivering the iodine-polystyrene NP liquid to the upper right lung, lower right lung, and entire lung, respectively, by 
controlling the position/depth of intubation cannula. f) Pixel-by-pixel intensity profiles along the linear trajectories across the 2D lung images (along the 
colored dashed lines in panels (b)–(e)) demonstrate that massive decreases in pixel intensity (compared to baseline in blue) result from the substantial 
deposition of iodine, while the fluctuations in the signal are due to, e.g., imperfect subtraction of the predelivery image.
www.advancedsciencenews.com www.small-journal.com
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the heart (dark region in the top center of the lung region) are 
clearly visible. By subtraction of the predelivery image from 
each image during substance delivery a difference image is 
obtained, which reduces the “background” signal from the 
rib cage, spine, and heart (Figure 2b). Consequently, this dif-
ference image more clearly shows the pulmonary distribution 
of the iodine-NP liquid, which in this case was directed to the 
left half of the lung by placing the intubation cannula beyond 
the first bronchial bifurcation (separating the left and right half 
of the lung). Moreover, the subtraction image also highlights 
the position of the main bronchi and boundaries of the lung, 
which provides guidance on localization of the delivered iodine-
NP solution which is useful for data interpretation. Figure 2c–e 
displays equivalent images for different delivery experiments 
via intratracheal instillation directed to the right upper, right 
lower, and whole lung, respectively, via proper positioning of 
the inserted cannula. Moreover, intensity profiles along (linear) 
trajectories across the 2D lung images depicted in Figure 2e 
illustrate the variability of the gray-scale signal for the dif-
ferent regions of these lungs, where lower signals correspond 
to regions of higher iodine dose (high X-ray absorption), indi-
cating the major locations of iodine-NP liquid (Figure 2f). This 
pixel-by-pixel analysis (pixel size: 10.4 µm) reveals massive loss 
of X-ray intensity in regions of substantial iodine deposition, 
while the fluctuations in signal originate from artifacts due to, 
e.g., imperfect background subtraction partially due to unavoid-
able slight position changes of the breathing mouse during the 
course of the substance delivery process.
Time-resolved in vivo visualization of the dynamic pro-
cess of liquid delivery via intratracheal instillation to the lung 
(see Videos S1 and S2 in the Supporting Information for left 
and whole lung delivery) reveals that the main delivery mecha-
nism is not only gradual spreading of the liquid from the point 
of entry (trachea/primary bronchus) to the more distal parts 
of the lung, but also by recurring liquid accumulation in and 
blocking of one of the airways followed by rupturing of the 
liquid blockage during breathing activity. This results in sec-
ondary spray/aerosol formation, which provides an efficient 
mechanism for bulk liquid reaching the distal parts of the lung.
2.2. Ex Vivo Multimodal Imaging of NP Distribution  
in the Lungs
After in vivo PB-PCXI each lung underwent ex vivo imaging 
using either LSFM or CT scanning followed by WLFI and 
LSFI (Figure 1b,c). Both imaging modes are mutually exclu-
sive, since the former requires wet fixation and optical tissue 
clearing, while the latter involves drying of the lung. Since the 
last in vivo PB-PCXI image corresponds to the ex vivo images, 
the agreement between in vivo PB-PCXI and ex vivo imaging 
modalities can be assessed. Figure 3 presents an example of 
this data set after slow-instillation of 100 µL iodine-NP solu-
tion. The pseudocolored PB-PCXI difference image that is over-
laid with a directly obtained image clearly indicates two main 
regions of iodine-NP deposition, one in the upper right lung 
and the other around the diaphragm (Figure 3a and Video S3, 
Supporting Information). 3D reconstructed ex vivo lung from 
a CT scan of the same subject depicts a qualitatively consistent 
distribution profile with preferential right superior lobe tar-
geting and some near-diaphragm postcaval lobe deposition 
(Figure 3b and Video S4, Supporting Information). This distri-
bution pattern is also found by WLFI (Figure 3c and Figure S2, 
Supporting Information) and LSFI (Figure 3d).
Ex vivo fluorescence LSFI allows for quantitative analysis of 
the regional targeting of fluorescence substances. Lungs from 
nine independent slow-instillation experiments were stratified 
for preferentially left and right as well as uniform (global) NP 
deposition in the lung. The ratios of the fluorescence intensi-
ties from the right and left lung, which are normalized to their 
respective right and left lung volume to account for the effect 
of volume-dependent lung ventilation,[27,28] reveal that for global 
delivery the ratio is equal to unity and a 3.7-fold preferential tar-
geting of the right (3.7) and left (3.7 = 1/0.27) half of the lung was 
accomplished, respectively (Figure 3e). Finally, the delivered dose 
was determined from quantitative fluorescence analysis using 
dose-intensity conversion curves based on two reference lungs 
containing known amounts of polystyrene-SkyBlue NPs (using 
regular intratracheal instillation) and three nontreated lungs 
for tissue-autofluorescence correction.[27,29] In this context it is 
important to note that the presence of iodine did not affect the 
fluorescence signal from SkyBlue NPs (Figure S3, Supporting 
Information). In the present experiments, 50 and 100 µL were 
applied via intratracheal slow-instillation at a constant delivery rate 
of (4.2 µL s−1) and 72.98 ± 36.21% and 79.9 ± 24.1% of the nom-
inal dose was delivered to the lung, respectively (Figure 3f), where 
for one of the 50 µL lungs almost nothing (<7%) reached the lung 
probably due to accidental withdrawal of the intubation cannula 
during the delivery procedure. Hence, no significant difference in 
deposited fraction of applied dose/volume was found for different 
volumes via slow-instillation (between 50 and 100 µL). It also 
reveals that slow-instillation of 50 µL liquid yields the same frac-
tional deposition as reported for regular instillation 77.2 ± 14.2% 
(50 µL in <1 s; no data for 100 µL are available).[29] Quantitative 
analysis with any of the other imaging modalities is difficult due to 
substantial tissue attenuation for whole lung fluorescence imaging 
and challenges in separating X-ray contrast seen from the treat-
ment and the X-ray contrast seen from the living anatomy.
In summary, this analysis shows that in vivo X-ray and ex 
vivo X-ray and fluorescence imaging approaches show quali-
tatively consistent pulmonary deposition patterns for intratra-
cheal slow-instillation, which indicates co-localization of X-ray 
and fluorescence-active agents. Moreover, LSFI allows for 
quantitative dosimetry analysis of fluorescent NPs. The data 
presented here also show that positioning of the intubation 
cannula beyond the first bifurcation of the bronchial tree allows 
for regional targeting of liquid substances into the left or right 
half of the lung, but deliberate selection of either the right or 
left half is difficult. Finally, regular and slow-instillation provide 
similar substance delivery efficiency (≈75%) with somewhat 
better dose reproducibility for regular instillation.
2.3. Visualization of Small-Volume Slow-Instillation  
by Multimodal Imaging
Visualization of extremely small amounts of bulk liquid (4 µL) 
delivery throughout the entire murine lung with ≈1000 µL total 
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lung volume (600 cm2 epithelial surface area) via intratracheal 
instillation is notoriously difficult. It has been reported that 
addition of lung surfactant could facilitate pulmonary delivery 
both in terms of speed of dispersion and uniformity of distri-
bution as surfactant is known to reduce surface tension of the 
applied bulk liquid.[30] In this case, the mouse was intubated for 
syringe-assisted slow-instillation, but breathing spontaneously 
and in vivo X-ray image acquisition (100 ms per breath) near 
the end of inhalation was triggered by monitoring the motion 
of the chest with an optical displacement sensor.[31] In vivo 
PB-PCXI revealed that delivery of 4 µL of iodine-polystyrene 
NP liquid resulted in highly localized, small puddles of liquid 
into either the right or left lung, but not to both sides (Figure 4a 
and Video S5, Supporting Information). Only the proximal 
bronchial region was reached and addition of surfactant did not 
affect delivery speed or localization of the liquid as shown in 
Figure 4d and Video S6 (Supporting Information). The small 
amounts of iodine delivered to the lungs were below the detec-
tion limit of ex vivo CT as seen from Figure 4b,e. On the other 
hand, ex vivo WLFI was able to detect the fluorescence signal 
in the left half of the lung (red in Figure 4c,f) confirming the 
distribution observed with in vivo PB-PCXI. Quantitative 
dosimetry based on LSFI (Figure 4g) revealed no statistically 
significant effect of lung surfactant on the delivered dose frac-
tion of 4 µL iodine-NP liquid (with and without surfactant: 
0.71 ± 0.19 and 0.53 ± 0.28, respectively). In fact this delivery 
fraction is also consistent with the corresponding values for 
50 and 100 µL of liquid instillation (Figure 3f).
2.4. Real-Time Monitoring of Particle Delivery by PB-PCXI:  
Gold, Iron Oxide, and QDs Delivery
In the experiments reported above iodine was added to the NP 
suspension, since the polystyrene NPs cannot be detected by 
X-ray analysis. Substances with a high atomic number or den-
sity, such as iodine, lanthanide, gold, or bismuth-based mate-
rials, are preferable to be used as X-ray contrast agents because 
of their high absorption cross section.[32] Recently, utilization of 
NP-based X-ray contrast agents has been intensively discussed 
for diagnostic and molecular imaging, as NPs provide the 
potential of high loading of contrast agents and the possi-
bilities of surface modification enhancing cell/organ-specific 
targeting. Traditionally, gold NPs have been used as X-ray con-
trast agents for, e.g., imaging tumor targeting of NPs via proper 
surface functionalization after intravenous injection in vivo.[33] 
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Figure 3. In vivo and ex vivo imaging modalities show consistent end-delivery distribution of an intratracheally slow-instilled iodine-nanoparticle 
suspension in the lungs (posterior view). a) A pseudocolored difference image (analogous to Figure 2b) overlaid with a directly obtained X-ray image 
(analogous to Figure 2a) allows for co-mapping of lung morphology and iodine-polystyrene NP deposition, indicating preferential delivery to the supe-
rior and postcaval lobe of the right lung (green and blue arrows, respectively). b) Matching bi-lobal delivery was also observed from an ex vivo CT scan. 
Ex vivo fluorescence images obtained from c) WLFI and d) LSFI further indicate the success of right lung delivery. Due to tissue-induced light attenua-
tion, the fluorescence signal from the near diaphragm postcaval lobe is not visible in posterior view (c) but clearly evident in anterior view (Figure S2c, 
Supporting Information). e) Right/left deposition ratios of NPs normalized to the respective right/left lung volume ratio were measured quantitatively 
with WLFI, displaying the success of preferential right or left delivery (PRD or PLD) and global lung delivery (GLD). f) Quantitative determination of 
the dose/volume of liquid delivered to the whole lung using the LSFI data for 50 or 100 µL of applied liquid.
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However, gold NPs have rarely been used as X-ray contrast 
agent for pulmonary delivery. This study visualizes the dynamic 
process of pulmonary delivery of three types of particles (two 
out of the three are NPs) in real time using in vivo PB-PCXI.
Figure S4 (Supporting Information) shows five consecu-
tive PB-PCXI frames revealing the temporal evolution of the 
NP delivery process during nasal aspiration of 40 µL gold NP 
suspension (delivered to one nostril of the mouse with a rate 
of 0.16 µL s−1). The pseudocolored difference images high-
light the location of the NP suspension. The gold NP suspen-
sion initially forms an increasing drop at the tip of the syringe 
and—once large and close enough to the nostril—the droplet 
is suddenly inhaled (aspirated) and deposited in the left half 
of the nasal airways and eventually draining down passed 
the glottis into the trachea into the left primary bronchus as 
observed in Video S7 (Supporting Information) and even into 
the deep lung. The sequence of images in Figure 5a,b displays 
the temporal evolution of NP delivery into the deep lung via 
intratracheal slow-instillation of 100 µL of a mixture of iron 
oxide and (fluorescent) melamine particles and pure QDs, 
respectively. Clearly, the iron oxide particles (2.5 mg mL−1) were 
delivered quite uniformly throughout the targeted left half of 
the lung (Figure 5a), albeit the image contrast is not as good 
as for iodine (92.5 mg mL−1), which is at least in part due to 
the lower mass concentration/dose of iron oxide particles. 
The QDs were delivered to the whole lung (Figure 5b) and 
the mechanism of delivery is a relatively slow and continuous 
transport (several seconds) of a film of particle liquid (position 
indicated by arrow) from the trachea to the deeper regions of 
the lung. Also, similar to iron oxide, the lower mass dose of 
QDs (0.4 × 10−6 m) results in lower contrast compared with 
iodine (92.5 mg mL−1). Relatively uniform distribution of QDs 
throughout the lung into the distal airways and alveoli makes 
it even difficult to visualize. The dynamic processes of instil-
lation delivery for iron oxide particles and QDs are shown in 
Videos S8 and S9 (Supporting Information), respectively. Of 
note, QDs are particularly interesting, as they can serve as 
contrast agent for both X-ray and fluorescence imaging.
2.5. Cellular Localization of NPs Revealed by Ex Vivo  
Tissue- Cleared LSFM in Nondissected Lungs
None of the imaging modalities above offers the possibility 
for 3D visualization of NP localization with cellular resolution 
throughout the entire mouse lung. While CT scan and LSFI 
offer 3D imaging capabilities, they do not allow for NP localiza-
tion within individual cells. We recently demonstrated that ex 
vivo LSFM allows for quantitative co-mapping of lung architec-
ture and NP deposition with single-cell resolution in nondis-
sected but optically cleared lungs.[27] Here we apply this method 
to study the pulmonary distribution of 100 µL of an NP sus-
pension after intratracheal slow-instillation. Figure 6 shows the 
general agreement of the whole lung distribution as observed 
by PB-PCXI and LSFM for iodine-melamine NPs (Figure 6a,b), 
iron oxide-melamine NPs (Figure 6d,e), and QDs (Figure 6g,h). 
At cellular resolution (pixel size <1 µm) melamine NPs were 
found mainly deposited in the bronchi as well as the bron-
chioles and proximal part of the alveolar duct (Figure 6c), the 
so-called proximal acinar region. Similar results were found 
for iron oxide and (fluorescent) melamine NPs delivery how-
ever with a more preferential delivery to the left half of the lung 
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Figure 4. Determination of small-volume (4 µL) intratracheal slow-instillation of iodine-NP suspension a–c) in the absence and d–f) presence of 
alveolar surfactant by multimodal imaging. Representative 2D images with in vivo PB-PCXI show the highly localized delivery of 4 µL iodine-polystyrene 
NP liquid without (a) or with (d) surfactant. The X-ray signal is below the detection limit of 3D reconstructed images from ex vivo CT ((b) and (e)), 
while 2D images obtained from ex vivo WLFI exhibit the proximal bronchial distribution of iodine-polystyrene NP liquid ((c) and (f)), albeit more diffuse 
then in (a) and (d) due to tissue-induced light scattering. The presence of surfactant had no effect on the speed of liquid dispersion and uniformity of 
distribution. g) The deposited fractions of 4 µL slow-instillation without or with surfactant based on LSFI data.
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distribution (Figure 6d,e). Also the small amount of melamine 
NPs delivered to the right lung was preferentially located in the 
distal small airways (bronchioles) and proximal alveolar region 
(entrance of alveolar sac) (Figure 6f). Finally, Figure 6g displays 
the QDs distribution profile in the whole lung imaged by PB-
PCXI and the regions of high QD dose are indicated by red 
arrows. It is evident that in this case QDs were distributed to 
all five lung lobes but did not transport into the peripheral lung 
(Figure 6h) reaching only a few localized small alveolar regions 
(Figure 6i). An animation of the distinct 3D distribution pro-
files of QDs in whole murine lung measured by LSFM can be 
seen in Video S10 (Supporting Information).
2.6. Multimodal Imaging for Comprehensive Deciphering  
of the Characteristics of Aerosol Inhalation
The clinically most relevant route of pulmonary drug delivery 
is aerosol inhalation. Here an iodine-NP liquid was delivered to 
the lung via ventilator-assisted inhalation of aerosols. Since indi-
vidual aerosol droplets are too small for direct imaging (2–4 µm 
diameter) and their liquid/contrast delivery rate was extremely 
small (8.6 nL s−1; ≈490-fold smaller than slow-instillation), 
in vivo PB-PCXI is very challenging. In order to visualize 
the dynamic delivery process of aerosol inhalation, a large 
volume of NP-iodine liquid was nebulized (225–300 µL) and 
quantitative fluorescence spectroscopy in tissue homogenates 
revealed that 3.7 ± 1.1% and 5.6 ± 2.3% of the applied volume 
was deposited in the lung lobes and the trachea, respectively 
(Figure 7j).[34] It is noteworthy that from quantitative spectro-
fluorometry of the lung slices (LSFI) one obtains a deposited 
aerosol fraction of 15.6 ± 2.8 % (whole lung) (Figure 7j), which 
is significantly larger than the 9.3 ± 2.3% (trachea + lung lobes) 
measured in lung/trachea homogenates, probably due to the 
higher light attenuation in sliced lung tissue. Since we consider 
tissue homogenization as more accurate method of LSFI,[27,34] 
we report 8.6 and 12.9 nL s−1 as pulmonary and tracheal aer-
osol deposition (delivery) rate, resulting in 5.6 and 8.3 µL NP 
liquid out of applied 150 µL volume deposited in the lung and 
trachea, respectively. Not surprisingly, in vivo PB-PCXI showed 
no iodine-related signal during aerosol application (Figure 7a) 
due to the low iodine delivery rate and the extremely uniform 
distribution of (aerosolized) iodine throughout the lung. On 
the other hand, gradual accumulation of iodine in the lung 
over the entire inhalation period (10 min and 48 s) was suffi-
cient for obtaining a clear iodine signal from in vivo PB-PCXI 
(Figure 7a–d and Video S11, Supporting Information).
Moreover, in vivo PB-PCXI was useful to resolve unexpected, 
nonaerosol related secondary liquid re-distribution mecha-
nisms, which can occur during ventilator-assisted aerosol inha-
lation. Unlike instillation, which shows a relatively patchy liquid 
distribution in the lung (Figure 6b), aerosol inhalation spreads 
the relatively small lung-deposited dose uniformly throughout 
the entire lung as can be clearly seen from ex vivo 3D recon-
struction of the lung from CT scan (Figure 7e), ex vivo WLFI 
(Figure 7f), and ex vivo tissue-cleared LSFM (Figure 7g–i). 
During the process of ventilator-assisted inhalation localized 
accumulations of liquid were observed in the upper airways 
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Figure 5. Real-time monitoring of pulmonary delivery of pure particles by in vivo PB-PCXI. a,b) Difference image sequences of the intratracheal slow-
instillation of 100 µL iron oxide (mixed with fluorescent melamine NPs) and pure QDs at 24 s (4.2 µL s−1) to the mouse lung, respectively. The iron 
oxide particles were delivered quite uniformly throughout the left lung (results from placing the intubation cannula beyond the first bifurcation) (a) and 
QDs were distributed to the whole lung (b). Compared to iodine the reduced image contrast is in part due to the lower delivered particle dose. Arrows 
indicate the formation of liquid accumulations that do not completely block the airways (no secondary aerosol formation) but gradually slide down the 
airway tree. The increased background noise (e.g., rib cage morphology) is due to unavoidable mouse movements and the lower contrast of pure NPs 
as compared to iodine. The time axis indicates real time in seconds after the first image in which time was set to 0 s.
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near the trachea (Figure 7b, arrow), which were gradually trans-
ported to the lower airways (Figure 7c, arrow) and into the bron-
chiolar region where they dispersed (Figure 7d, arrows) into 
even smaller liquid accumulations as evidenced by fluorescence 
“hot spots” seen in LSFM (Figure 7h, arrows). Not only the 
presence but also the origin of these occasional accumulations 
of liquid in the lower bronchial region can be understood from 
multimodal imaging. Ex vivo whole lung imaging (Figure 7f,g) 
and quantitative fluorometric dosimetry (Figure 7j) provide evi-
dence for substantial aerosol deposition in the trachea (≈60% 
of the total deposited aerosol dose is deposited in the trachea). 
Since the murine trachea is a rather narrow duct, it is conceiv-
able that the trachea-deposited aerosol will eventually block the 
trachea resulting in spillover of some of the liquid in the tra-
chea into the upper airways and from there into the bronchiolar 
region as observed by in vivo PB-PCXI (Figure 7b–d) and ex 
vivo LSFM (Video 12, Supporting Information). As this spillover 
typical occurred after 95 s during nebulization, we conclude 
that at least 1.2 µL (12.9 nL s−1 × 95 s) of liquid has to get accu-
mulated in the trachea for occurrence of the spillover, which 
corresponds to 22 µL of nebulized liquid (= 1.2 µL/0.056).
3. Discussion
Aerosol delivery of drug/NM is the most widely used applica-
tion route for treatment of lung disease.[35,36] Targeted delivery 
of drug/NM on a regional and even cellular scale is of cen-
tral importance for precision medicine especially for localized 
lung diseases such as lung cancer, asthma, emphysema, or 
COPD.[3,37] Also inhalation of ambient NPs is one of the main 
health hazards associated with NPs.[38,39] The region of NM/NP 
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Figure 6. In vivo PB-PCXI and ex vivo tissue-cleared LSFM for cellular-resolution visualization of NP-liquid localization in nondissected whole murine 
lungs after slow-instillation (100 µL of liquid). a) The PB-PCXI difference image shows the pulmonary distribution of an iodine-melamine NP suspen-
sion after instillation, which is consistent with the result obtained from b) 3D reconstructed LSFM image. c) A 2D image with cellular resolution further 
reveals the specific NP localization. Images obtained from d) in vivo PB-PCXI and e) ex vivo LSFM distinctly show preferential left lung distribution of 
a mixture of iron oxide particles with melamine resin NPs. f) NP deposition in distal small airways (bronchioles) and proximal alveolar regions was 
revealed by 2D images in single cell resolution. For QD application g–i) a similar set of images shows that QDs were delivered to all five lobes with 
highest deposition in the distal part of the terminal bronchioles and the entrance of the alveolar duct. Green: tissue autofluorescence; red: melamine 
NPs ((b), (c), (e), and (f)) or QDs ((h) and (i)).
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deposition can have a significant impact on residence time, 
release kinetics, and hence bioactivity of the drug or toxicity 
of NPs.[40,41] While NM/NP can be quickly (within minutes) 
removed from the upper airways by mucociliary transport, 
clearance of NM/NP from the alveolar epithelium mainly 
relies on uptake by alveolar macrophages (takes a few hours), 
which may be enough time for direct bioactivity/toxicity of the 
NM/NP or result in secondary drug release into or from the 
macrophages.[2] Consequently, understanding the mechanisms 
of pulmonary NM/NP delivery and their relevance for tissue-
delivered NM/NP dose with cellular resolution is essential for 
the development of effective NM[42] or minimizing health haz-
ards of NPs.[43] Standard histological analysis or single-modality 
imaging techniques cannot resolve the entire delivery process 
in all relevant temporal (seconds to days) and spatial scales 
(whole lung to cellular).[44] This is also the case for the preclin-
ical efficacy or toxicity testing of NM/NP using animal models.
In this study we combined in vivo X-ray and ex vivo fluo-
rescence imaging modalities to investigate the dynamic pro-
cess of pulmonary NM delivery and its impact on pulmonary 
NM distribution with high temporal and spatial resolution in 
murine lungs. PB-PCXI utilizes differences in X-ray refractive 
index and associated phase shifts at air–tissue interfaces for 
enhancing soft tissue contrast (e.g., in the lung) as compared 
to X-ray absorption.[26] Building on our previously published 
in vivo PB-PCXI studies in murine lungs,[18,24] the present 
study demonstrates that combined in vivo PB-PCXI and ex 
vivo fluorescence imaging can provide complementary infor-
mation, which enhances the understanding of complex pro-
cesses such as NM/NP delivery to the lung in a quantitative 
way on various scales (whole lung to cellular). The strengths 
and weaknesses of all five imaging modalities used here are 
summarized with respect to 2D/3D imaging capability, resolu-
tion, fidelity (conservation of original anatomical 3D structure), 
anatomical information, and technical complexity as summa-
rized in Table 1. In general, X-ray imaging is used here for in 
vivo imaging at high temporal resolution (1 Hz), while ex vivo 
fluorescence imaging provides insight into spatially resolved 
dosimetry.
In preclinical lung research, instillation or aspiration of bulk 
liquids is the most widely used method of pulmonary drug 
delivery. On the other hand, aerosol inhalation—not bulk liquid 
application—is the preferred route of drug delivery in clinical 
settings. In spite of their widespread use detailed information 
on the dynamic details of the application processes and spa-
tially resolved dosimetry is scare. All three application routes 
have been investigated in this study, but a significant focus was 
on ventilator-assisted aerosol inhalation, since it offers a tech-
nologically mature, efficient (≈4% of invested dose is delivered 
to lung) and dose-controlled method for physiologic delivery of 
liquid substances to the lungs of animal models (here mice) 
using a commercially available device (flexiVent system, 
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Figure 7. Leveraging multimodal imaging for a comprehensive understanding of the characteristics and delivery mechanism of ventilator-assisted 
aerosol inhalation. a) Time-resolved visualization of 150 µL aerosol inhalation (takes 10 min and 48 s) with in vivo PB-PCXI shows no obvious X-ray 
signals during the entire period of aerosol delivery (iodine-polystyrene NP suspension). However, occasional appearance of localized accumulations of 
liquid could be observed b) (light blue arrow) in the upper airways, which were then gradually transported to c) (light blue arrow) the lower airways and 
finally dispersed d) (yellow arrows) in the bronchiolar region. a–d) The time (mm:ss) noted in the left upper corner of the images indicate the time after 
start of aerosol inhalation. The 3D and 2D images from e) ex vivo CT and f) WLFI, respectively, exhibit the whole lung liquid distribution, but only WLFI 
provides a differentiated deposition profile matching end-inhalation PB-PCXI. g–i) The LSFM images, which were obtained for a different lung after 
aerosol inhalation of 40 µL melamine NP suspension, show high deposition at the end of the intubation cannula in the trachea (g) and very uniform 
deposition throughout all lung lobes (h) especially in the proximal acinar region (bronchioles and proximal part of alveolar duct) with the exception 
of a few “hot spots” in the bronchioles ((h), yellow arrow), which can be rationalized by the features (yellow arrows) observed by PB-PCXI (d). i) 2D 
cellular visualization of NP deposition in lung tissue. j) Determination of the deposited fraction of the applied aerosol dose in all lung lobes, trachea, 
and whole lung (lung lobes + trachea) using quantitative spectrofluorometry in lung homogenates (homo) or on lung slices (LSFI).
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EMKA/SciReq Inc.). As such it has the potential to at least par-
tially replace intratracheal instillation and nasal aspiration in 
future preclinical inhalation drug or toxicity testing.
It is evident that intratracheal instillation allows for highly 
efficient (76.3 ± 23.0% of invested dose reaches the lung), 
dose-controlled delivery of liquids (repeatability: 30.1%) for all 
tested liquid volumes (4–100 µL) into the deep parts of the lung 
(bronchioles and even alveoli). It is not intuitively clear how a 
bulk liquid injected into the trachea via intratracheal instillation 
can reach the deeper parts of the lung. In vivo PB-PCXI revealed 
that the instilled bulk liquid is not primarily flowing down the 
bronchial tree, but is distributed quite uniformly throughout 
the lung by secondary aerosol formation due to occasional 
blockage of the airways with liquid and subsequent bursting 
of this blockage during breathing activity (Videos S1–S3, 
Supporting Information).[24] As mentioned above, the slow-
instillation process (24 s for 100 µL; 4.2 µL s−1), which was used 
here for the sake of in vivo PB-PCXI imaging, is not identical to 
the typically used, rapid manual instillation (<1 s, >50 µL s−1). 
However, the main features of pulmonary fluorescence distri-
bution and the measured delivery efficiency (76.3 ± 23.0%) are 
in excellent agreement with observations for rapid instillation 
(77.2 ± 14.2%) as provided by Barapatre et al.[29]
In vivo PB-PCXI also provides valuable insights into the 
mechanisms of pulmonary NM/NP delivery via ventilator-
assisted aerosol inhalation. As expected there is a very gradual, 
uniformly distributed increase in X-ray signal with no burst-like 
events as seen for intratracheal instillation, which is related to 
aerosol deposition in the lung occurring uniformly at a rela-
tively low delivery rate. However, even for ventilator-assisted 
aerosol inhalation we observed occasional localized accumu-
lations of liquid in the upper airways near the trachea, which 
were gradually flowing down the airway tree reaching even the 
bronchiolar region (Figure 7b–d). Fluorescence imaging and 
fluorescence-based dosimetry revealed that a large fraction 
of the aerosol dose is deposited in the trachea (≈60% of total 
deposited dose) due to the spray-like aerosol stream exiting the 
narrow intratracheal intubation cannula. Since direct aerosol 
deposition in the bronchial tree would result in a more gradual 
process of liquid accumulation, spillover from the trachea is the 
most likely reason for this to occur. From the measured deposi-
tion rate (based on fluorescence) and the time of first occur-
rence of liquid accumulation in the airways (in vivo PB-PCXI), 
we determined that this nonaerosol-related transport effect 
occurs if more than 22 µL of liquid is nebulized. The critical 
liquid volume of 22 µL is expected to depend on positioning of 
the mouse and on ventilation parameters (breathing frequency, 
tidal volume, length of breath hold, and inhalation-to-exhalation 
time ratio). In our case, the mouse was held in upright position 
(for the sake of in vivo PB-PCXI), while for typical aerosol appli-
cations the mouse is laying horizontally on its back. Therefore, 
we recommend nebulizing as little volume as possible with the 
flexiVent ventilation system to avoid nonaerosol-related lung 
delivery processes. However, even with this artifact the delivery 
of NPs to the lung is much more uniform with ventilator-
assisted aerosol inhalation than with intratracheal instillation 
on a whole lung, regional, generation, and cellular scale. It is 
important to note that the initially unexpected fluorescence 
“hot spots” detected with LSFM in the deeper bronchial region 
(Figure 7h) could not have been explained without the informa-
tion provided by in vivo PB-PCXI.
A prerequisite for combing X-ray and fluorescence imaging 
is that the co-applied active agents (X-ray absorption and 
fluorescence activity) have the same deposition profile in 
the lung. Since both agents are applied as liquid mixture, 
this is to be expected. This was confirmed for all contrast/
fluorescence agents/mixtures used here (Table 1)—not just the 
clinically approved iodine—as evidenced by the excellent 
qualitative agreement of the spatial distribution profiles for 
all imaging models covering different volumes (4–100 µL), 
different localization (left, right, whole lung), and different 
degrees of spatial uniformity (patchy or uniform) of the applied 
liquid. QD is the only type of contrast agent (NP) that is both 
X-ray and fluorescence active.
Limitations of the X-ray imaging modalities were mainly 
related to the signal-to-noise ratio for low amounts of liquid 
or very uniformly distributed contrast agents. For instance 
ex vivo CT reached its detection limit for localized delivery of 
4 µL (iodine-NP solution with 92.5 mg mL−1 iodine) of bulk 
liquid and uniformly distributed aerosol (11 µL) (Figure 4b,d 
and Figure 7e). Also in vivo PB-PCXI was difficult, but not 
impossible, for the latter case. On the other hand, fluorescence 
imaging on dried lungs (especially on whole lungs; WLFI) was 
prone to widen the apparent region of particle deposition due 
to tissue-related light scattering effects, which can be largely 
eliminated by tissue clearing combined with LSFM.
As mentioned above, most of the standard imaging modali-
ties (e.g., PA, US, CT, SPECT, PET, and MRI) are unable to vis-
ualize pulmonary fluid delivery dynamics at 1 Hz under in vivo 
conditions in mice mainly due to the poor spatial and temporal 
resolution.[16] Recently, some multimodal imaging techniques 
have been used for determination of NP biodistribution and 
bioactivity in preclinical research. For instance, a combination 
of triple imaging techniques (i.e., dark-field light microscopy, 
electron microscopy, and nanoscale secondary ion mass spec-
trometry) was used to study the NP interaction with green algae 
in the context of NP localization, internalization, and chemical 
identity.[45] Also, quantitative imaging of co-localization of tumor 
associated macrophages with therapeutic 64Cu-labeled polyglu-
cose nanoparticle in an orthotopic model of lung adenocarci-
noma was accomplished via PET, in vivo confocal microscopy, 
and tissue-cleared LSFM.[46] PCXI has already been applied for 
ex vivo and in vivo studies on mucociliary transport of large 
microparticles or 5–100 µm fibers in the trachea or upper air-
ways of animal models such as mice and pigs[26,47–49] and for 
monitoring the delivery of liquids to murine lungs via nose or 
intubated cannula delivery.[16–18,25] Moreover, several common 
bulk particulates (e.g., lead dust, quarry dust, glass beads, 
asbestos, and Galena with size ≥ 5 µm) were tracked in live 
animal trachea airways by PCXI, showing the high variability in 
particle movement during mucociliary transport.[26,47,50] A few 
available NPs with high atomic number such as gold NPs, bis-
muth NPs, lanthanide-doped NPs, and tantalum pentoxide NPs 
as new contrast agents of X-ray-based modalities have also been 
studied for diagnostic and molecular imaging.[33] However, to 
the best of our knowledge, real-time monitoring of the pulmo-
nary delivery of NP suspensions has not been studied yet, and 
the combination of in vivo PCXI and quantitative and spatially 
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resolved ex vivo fluorescence imaging provided complementary 
insights into the mechanisms, regional/cellular distribution, 
and dosimetry of pulmonary drug delivery in mice. By virtue of 
bioactive fluorescent probes fluorescence imaging is also suit-
able for bioactivity studies.[43,44] In principle the five modes of 
imaging presented here can be reduced to two modalities, 
namely, in vivo PB-PCXI and one of the three fluorescence 
imaging modalities, which should be selected based on 
the experimental constraints (available time for sample and 
image processing, cost, spatial resolution, etc.).
The core issue of this study is to decipher the main features 
of the dynamic delivery process of NPs to the nose/lung and 
to characterize the initial 3D NP distribution profile immedi-
ately after varied routes of pulmonary delivery. Here, NPs were 
suspended in liquid and delivered either as bulk liquid (nasal 
aspiration, intratracheal instillation) or droplets (aerosol inhala-
tion). Consequently, the initial deposition profile of NPs mainly 
depends on liquid properties (e.g., delivery rate and droplet 
size). The more patchy, central deposition of QDs (Figure 6g) as 
compared to melamine NPs (Figure 6b) could be related to the 
higher viscosity of QD suspensions.[27] After deposition on the 
lung epithelium the liquid phase of the NP suspensions will 
be resorbed by lung tissue and re-distribution of NPs within 
the lung or out of the lung (biokinetics) will depend on NP 
properties including size, shape, chemical composition, and 
surface functionalization.[51,52] These secondary redistribution/
biokinetics issues are relevant for many therapeutic and toxi-
cological considerations, but beyond the scope of the present 
study. Nevertheless, they can be addressed with the imaging 
platform described here. A generation limitation of this study 
is the use of mixtures (iodine with SkyBlue, iron oxide with 
melamine NPs), which is not favorable for longitudinal study 
of NP biokinetics in the lungs as different components (active 
agents) possess their own pharmacokinetics. The development 
of bimodal contrast agents or novel NP formations suitable for 
both X-ray imaging and fluorescent imaging allows for com-
bined NP pulmonary delivery and biokinetics studies since it 
avoids the occurrence of artifacts due to the use of two poten-
tially interacting and/or differently behaving contrast agents. In 
this study, 20 nm QDs were successfully applied as an example 
for a bimodal NP. Alternatively, encapsulated or conjugated 
hybrid particles consisting of one fluorescent and one X-ray-
absorbing material, such as iodinated polymers or liposomes 
with fluorescent dyes that have been widely used for bimodal 
imaging of NP accumulation in tumors,[10,32,33,53] could be par-
ticularly useful in future pulmonary studies.
4. Conclusion
In this proof-of-concept study, we introduced and validated 
a multimodal imaging approach for comprehensive under-
standing of the mechanisms of pulmonary NP delivery in the 
context of dynamics of the delivery process, deposited dose, 
regional distribution, and cellular localization of NP in the 
(nondissected) whole murine lung. This imaging platform con-
sists of in vivo PB-PCXI, ex vivo CT, and three ex vivo whole 
and sliced-lung epifluorescence imaging or ex vivo LSFM on 
tissue-cleared lungs. While each of these imaging modes has 
strengths and weaknesses, selection of PB-PCXI and LSFM 
would not result in substantial loss of information. Mixing of 
particles as contrast agents for X-ray (iodine, gold NPs, iron 
oxide particles, and QDs) and fluorescence imaging (fluores-
cently labeled polystyrene or melamine NP and QDs) allowed 
for time-resolved (1.5 Hz) in vivo visualization of the dynamics 
of the pulmonary particle delivery process via intratracheal 
slow-instillation or ventilator-assisted aerosol inhalation with 
in vivo PB-PCXI. Moreover, in vivo and ex vivo X-ray particle 
distribution profiles were in good qualitative and quantita-
tive agreement with regional distribution patterns observed 
with fluorescence imaging techniques. This implies that the 
two applied contrast are co-localized during and directly after 
delivery. Our study also reveals that for intratracheal instillation 
of a bulk liquid the pulmonary distribution does not primarily 
occur via draining of the liquid down the bronchial tree, but 
by secondary aerosol formation associated with liquid blockage 
of airways and subsequent bursting of this blockage during 
breathing activity. In contrast, time-resolved in vivo imaging 
of the ventilator-assisted aerosol inhalation process revealed 
slowly accumulating uniform aerosol deposition throughout 
the lung with occasional transport of bulk liquid into the lung. 
The latter is likely due to direct impaction of aerosol spray 
exiting the intubation cannula resulting in liquid accumula-
tion in the trachea and eventual spillover into the bronchial 
region of the lung, if more than 22 µL of liquid is nebulized. 
This spillover explains the initially unexpected sporadic occur-
rence of ≈100–200 µm hot-spot regions in ex vivo LSFM lung 
images after ventilator-assisted inhalation. Development of 
bimodal contrast agents like QDs, which are suitable for both 
in vivo PXCI and ex vivo LSFM, is expected to be particularly 
useful for co-visualization of controlled pulmonary delivery of 
NP in real time and 3D biokinetics over long term. The present 
study thus describes a complementary multimodal imaging 
platform for high temporal and spatial resolution visualization 
of pulmonary NP delivery in a quantitative manner, which will 
accelerate the ability to target active NM/drugs to the diseased 
region of the lung and enhance the development and efficacy of 
the novel-designed NM.
5. Experimental Section
By virtue of concomitant multimodal in vivo and ex vivo imaging new 
insights into key aspects of common preclinical and clinical methods for 
pulmonary substance delivery are presented. The related materials and 
methods are described including the diverse set of imaging modalities 
and the panel of methods for pulmonary substance delivery.
Materials: Each of the imaging modalities required the use of 
materials with specific X-ray contrast or fluoroactivity.
For X-ray phase-contrast imaging, a clinically approved iodine-based 
contrast agent (Ultravist-370, 370 mg iodine per milliliter) and three 
types of metal NPs were used, namely, gold NPs ((volume median 
diameter (VMD)) 20.7 ± 9.7 nm), Roti-MagBeads (magnetic iron oxide 
embedded in silicium oxide surface coated with carboxylic groups, VMD: 
893.5 ± 348.9 nm, 10 mg mL−1, Carl Roth GmbH, Karlsruhe, Germany), 
and Qdot 800 ITK carboxyl QDs (emission at 800 nm; VMD: 18.1 nm 
± 6.5 nm Invitrogen, Ltd., Paisley, UK). Gold NPs were synthesized 
according to manufacturer instructions using 6 mg of gold (III) chloride 
trihydrate (HAuCl4·3H2O, ≥99.9%, Sigma-Aldrich) dissolved in 1 mL 
of deionized water. Then, 49 mL of water was added and the final gold 
solution was heated. When the gold solution started boiling, 0.94 mL 
Small 2019, 1904112
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of a 0.04 mol L−1 aqueous solution of sodium citrate (HOC(COONa)
(CH2COONa)2 · 2H2O, ≥99.0%, Sigma-Aldrich) was added to the gold 
solution, which was kept boiling for further 5 min. The solution changed 
color from transparent yellow to transparent gray, then black, and finally 
dark pink. Subsequently, the solution was taken from the heating plate 
and left stirring for 1 h in the dark, and then stored in the dark until use. 
The purchased QDs (stock solution: 8 × 10−6 m) were made from the 
crystals of a semiconductor material (CdSeTe), shelled with a ZnS layer, 
and further coated with a polymer layer with carboxylic groups.
For fluorescence-based microscopy, polystyrene NPs with the 
embedded fluorescent dye SkyBlue (excitation/emission (ex/em) 
= 670 nm/710 nm; VMD: 483.9 nm ± 122.3 nm; 10 mg mL−1; Kisker 
Biotech GmbH, Steinfurt, Germany), melamine resin fluorescence 
particles (MF, ex/em = 636 nm/686 nm; VMD: 498 ± 111.4 nm, 
microParticles GmbH, Berlin, Germany), and QDs were used. The 
commercial MF NPs (stock suspension: 25 mg mL−1) were prepared 
via an acid-catalyzed polycondensation reaction of melamine resin 
precondensates in the presence of selected fluorescent dyes in the 
aqueous phase.
Sizing of Nanoparticle Suspensions: Hydrodynamic diameter 
measurement of all NP suspension was performed with dynamic 
light scattering using a Malvern Zetasizer Nano instrument (Malvern 
Instruments Ltd., Malvern, UK) (Figure S1, Supporting Information). Of 
note, the observed increase of about 50% in VMD of polystyrene and 
melamine NPs when transferring them from water to iodine solution 
(from about 490 to 770 nm) (Figure S1, Supporting Information) 
possibly due to iodine-induced agglomeration did not adversely affect 
their fluorescence signals, which remained stable for more than a week 
after mixing (Figure S3, Supporting Information).
Animal Handling: Wildtype C57BL/6 female mice (age 9–18 weeks, 
19–25 g) were housed in individually ventilated cages (IVC-Racks; 
Bio-Zone, Margate, UK) supplied with filtered air in a 12 h light/12 h 
dark cycle. Mice were provided with food (standard chow) and water 
ad libitum. All procedures involving animal handling and experiments 
were carried out in accordance with protocols approved by the 
Regierung von Oberbayern (District Government of Upper Bavaria, 
AZ55.2-1-54-2532-108.13).
The animals were anesthetized by intraperitoneal injection of a triple 
combination of medetomidine (0.5 mg kg−1 body weight), midazolam 
(5 mg kg−1 body weight), and fentanyl (0.05 mg kg−1 body weight). 
The mice were then intubated by a nonsurgical technique using a 
20 G cannula with one side inserted into the trachea and the other 
side connected to a mechanical ventilator (flexiVent FX system, Scireq 
Inc., Canada), allowing for exact control over the breathing activity of 
the mouse during pulmonary application of liquids and during in vivo 
acquisition of images.
Methods of Pulmonary Substance Delivery: Three widely used 
techniques of pulmonary delivery of liquid substances were investigated 
here, namely, intratracheal instillation and nasal aspiration of bulk 
liquids, as well as (ventilator-assisted) inhalation of aerosolized 
liquids. For each of these methods time-resolved in vivo monitoring of 
pulmonary substance delivery throughout the entire lung was performed 
with PB-PCXI, which is described in detail below. However, the technical 
details related to PB-PCXI image acquisition deserve careful attention 
and are therefore included in this section.
For “intratracheal slow-instillation” delivery, the setting was similar 
to that depicted in previous studies.[24,25] The mice were mechanically 
ventilated at 90 breaths per minute, 30 mL kg−1 tidal volume, and an 
inhalation–inflation (breath-hold)–exhalation time ratio of 1:1:1. The 
liquid was introduced by a heat thinned PE10 polyethylene tube that 
was passed through the flexible wall of the ventilator inspiratory tube. 
The inner PE tube was small enough not to block the intubation cannula 
enabling simultaneous liquid delivery and mechanical ventilation. The 
liquid delivery (slow-instillation) was remotely controlled by a syringe 
pump (UltraMicroPump III and Micro4 controller, World Precision 
Instruments, Sarasota, FL) that allowed for both controlled liquid 
delivery from outside the imaging hutch and consecutive imaging during 
the whole instillation process. As listed in Table 1, 100 µL of various 
NP mixtures for combined X-ray and fluorescence imaging (SkyBlue-
iodine: 1:20 SkyBlue (stock suspension) and 1:4 iodine; melamine-iron 
oxide: 1:20 melamine and 1:4 iron oxide NPs) or QDs (1:20 dilution) 
was continuously delivered via the syringe pump to the trachea in ≈24 s 
(4.2 µL s−1). PB-PCXI image acquisition was performed triggered by the 
ventilator at a frame rate of up to 1.5 fps (frames per second) using a 
200 ms (100 ms for QDs) exposure during an end of inspiration 222 ms 
breath-hold phase.
To study the effect of alveolar surfactant (Alveofact 45 mg mL−1, 
Lyomark Pharma GmbH, Germany) on the pulmonary distribution 
of small amounts of liquids applied via intratracheal instillation, the 
delivery of a small volume (4 µL in 5 s, i.e., 0.8 µL s−1) of an iodine-
NP-surfactant mixture was investigated. The mixture contained 
1:4 diluted iodine and 1:20 diluted polystyrene-SkyBlue NPs with 
(+) or without (−) surfactant (25 mg mL−1) in distilled water. For this 
experiment the mice were spontaneously breathing so the ventilator 
was replaced with a noncontact fiber optic displacement sensor 
(RC-60, Philtec, MD) that was configured to detect respiratory motion 
and deliver an electrical trigger signal for image capture. The frame rate 
was maintained at 1.5 fps, but the exposure time was reduced to 100 ms 
to mitigate unavoidable motion blur due to the absence of a breath-
hold phase. It is noteworthy that for practical reasons the liquid delivery 
rates of 4.0 and 0.8 µL s−1 are slow compared to typical intratracheal 
instillation protocols delivering 50–200 µL within <1 s; by manually 
emptying a loaded syringe via the intubation cannula into the trachea 
at a delivery rate of >50 µL s−1. Since less than 1 s of delivery time is 
too short for reliable in vivo PB-PCXI imaging of different stages of the 
delivery process, slower delivery rates were chosen here, and image 
acquisition was performed as described above.
For “ventilator-assisted aerosol inhalation,” a similar protocol 
and setup as described for 100 µL instillation was used (80 breath 
per minute, 30 mL kg−1 tidal volume, 200 ms) and PB-PCXI image 
acquisition occurred during an end-inspiratory breath-hold phase as 
described above. In contrast to intratracheal slow-instillation, the inner 
PE10 polyethylene tube was removed and the ventilator was equipped 
with a nebulizer (Aeroneb Lab Small, Aerogen Inc., Galway, Ireland) 
in the inspiratory tubing for the generation and transport of liquid 
aerosol droplets to the lungs of mice. It was shown that for the 
flexiVent system operated under the conditions described above about 
4%–5% of the nebulized liquid was deposited in the lung (downstream 
of trachea), with the rest being deposited in the ventilation tubing 
or exhaled by the mouse.[27] Moreover, it was determined empirically 
that 150 µL was the maximum liquid volume that could be nebulized 
without at least partially blocking some part of the inspiratory 
ventilation tubing by accumulated rainout. Here, the nebulizer typically 
generated droplets with a liquid output rate of 0.26 mL min−1 and a 
volume-weighted median diameter of 2–4.0 µm. Here, the nebulizer 
was breath activated and active for 40 ms during the inspiratory phase. 
For a breathing rate of 80 breaths per minute this corresponded to an 
effective liquid output rate of 13.8 µL min−1 during flexiVent operation. 
Hence it took ≈10.8 min (870 breaths) to nebulize 150 µL liquid 
resulting in 5.6 µL of contrast agent deposited in the lung (3.7% of 
applied dose was deposited in the lung), where the dosimteric results 
from quantitative fluorescence spectroscopy in lung homogenates 
rather than the experimentally more uncertain LSFI results were 
relied on[34] (Figure 7g). The aerosol delivery rate to the lung was 
8.6 nL s−1 (=0.0086 µL s−1 = 5.6 µL/10.8 min). For some experiments, 
a second nebulization of 75 or 150 µL of liquid was carried out keeping 
the animal ventilated while drying the ventilation tube between 
nebulizations. For these experiments a 1:16 polystyrene NPs and 
1:5 iodine mixture in distilled water was used.
For “nasal aspiration,” a similar protocol was applied as reported by 
Gradl et al.[18] Briefly, a mixture of polystyrene NPs (1:10 dilution) and 
gold NP (1:2 dilution) suspensions was loaded into a syringe pump 
mentioned above, permitting controlled liquid delivery outside the 
imaging hutch. Here 80 µL of the polystyrene-gold liquid mixture was 
spontaneously inhaled via the nose by the mouse. The PB-PCXI frame 
rate was maintained at 1.5 fps with the exposure time of 100 ms.
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In Vivo PB-PCXI: All X-ray imaging experiments were carried out at 
an inverse Compton scattering source—the MuCLS located at the 
Technical University of Munich (TUM) in Garching, Germany. The 
source itself was developed and installed by Lyncean Technologies 
Inc. (Fremont, USA),[54,55] and the X-ray beamline infrastructure was 
designed and developed by TUM researchers. The source delivered a 
quasi-monochromatic and low divergence (4 mrad) X-ray beam. 25 keV 
X-rays with flux up to 2 × 1010 ph s−1 were used. The principle behind 
propagation-based phase-contrast imaging was to use free space 
propagation of a partial spatial coherent beam (typically around 1 m) 
after penetrating a sample to introduce additional contrast. As the x-ray 
wavefield propagated from the sample to the detector the sample-
associated phase modulations of the X-ray wavefront were converted 
into intensity modulations, which could be directly measured by a 
high-resolution X-ray detector. Here the propagation distance (sample-
to-detector distance) was chosen to 1 m. There images were recorded 
by an Andor Zyla 5.5 sCMOS camera (2560 × 2160 pixels), combined 
with a 20 µm thick Gadox scintillator (Gd2O2S:Tb) (CRYTUR, spol. 
s r.o., Czech Republic) deposited on a 2:1 fiber optic taper, resulting 
in 13 µm detector pixel size. The source-to-sample distance was 4 m, 
leading to a geometric magnification of m = 1.25, an effective pixel size 
of 10.4 µm, and a beam diameter of about 16 mm. As the X-ray beam 
had a fixed horizontal orientation, mice needed to be positioned in a 
head-high position. Therefore, mice were placed in a specially designed 
mouse holder on an x–y–z rotation stage to facilitate positioning in the 
X-ray beam.[31]
The pseudocolored images in Figures 3 and 4 are a composition of 
the raw PB-PCXI images (gray scale) overlaid with the colored difference 
image,[24] from which a predelivery image was subtracted to highlight 
the location of the contrast fluid similar to the analysis performed in 
Donnelley et al.[25] Images were aligned before color coding via a cross-
correlation-based image registration.
Ex Vivo Lung Tomography: After intratracheal instillation or aerosolized 
delivery of one of the liquid NP suspensions described above, mice were 
sacrificed immediately by exsanguination while anaesthetized, the lung 
was transcardially perfused for blood removal, and subsequently excised 
and either dried and inflated or optically cleared for subsequent ex 
vivo imaging (for a summary see Figure 1). Some of the excised lungs 
were mildly dried and inflated at a constant air pressure of 20–23 cm 
water in a microwave oven with the lowest power (10%). The lung 
tomography was performed on the excised, dried, and inflated lung 
prior to fluorescence-based microscopy. 2049 projections over 360° were 
captured and reconstructed with a standard fbp-reconstruction analysis. 
The 3D data were rendered using AVIZO or Bitplane Imaris (http://www.
bitplane.com/imaris/imaris).
Ex Vivo Tissue Fluorescence Imaging: Followed by CT scan of 
dried lungs, the ex vivo WLFI was performed using an IVIS (in vivo 
imaging system, Lumina II, Caliper/Perkin Elmer, USA) equipped with 
ex/em filters (ex/em = 640 nm/Cy5.5) suitable for the fluorescent NPs 
(SkyBlue). Subsequently, the dried lungs were embedded in polyurethane 
foam (PU foam Pattex Ultraweiss, Pattex, Germany) and sliced 
progressively perpendicular to the lung axis at an interval of 1 mm. After 
each slicing step, white light and fluorescence images of the block face 
and the 1 mm slice (Figure 3d) were recorded with the IVIS using ex/em 
= 640 nm/Cy5.5 filter. Similar IVIS imaging settings were used for all the 
lungs (exposure time = 2 s, binning = 1, field of view = 5, and f-stop = 1; 
this could be increased if saturated images occurred). Each 1 mm slice 
was imaged from both sides (top view and bottom view).
NP Dosimetry for the Iodine-NP-Treated (Instilled and Inhaled) Lungs: 
The autofluorescence in each NP-treated lung was subtracted to 
yield absolute fluorescence intensity induced by SkyBlue NPs. Three 
nontreated lungs were set as the background fluorescence and four 
typically fast-instilled lungs (50 µL 1:10 diluted or 100 µL 1:20 diluted 
SkyBlue NPs) were used to establish the intensity–dose standard curve 
for NP dosimetry (Figure S5, Supporting Information). Note that for four 
regular instilled lungs the SkyBlue liquid was directly injected into the 
mouse lung via the trachea,[27,56] which was different from the protocol 
used for the slow-instilled lungs (e.g., 24 s for 100 µL liquid delivery). 
The fluorophore dose in a whole lung should be principally proportional 
to the sum of absolute fluorescence intensities from all 1 mm slices. 
After yielding the desired fluorescence intensity–dose conversion curve, 
quantitative measurement of the deposited dose in those lungs could be 
achieved. The left/right/whole lung deposition analysis was carried out 
in the ex vivo WLFI data. The background intensity was subtracted to 
yield the absolute fluorescence intensity of SkyBlue for each part and the 
fluorophore intensity could be compared.
Ex Vivo Tissue-Clearing LSFM: Other nondried lung samples were 
optically cleared with a modified version of the 3DISCO protocol[57] as 
described in our recent study.[27] Briefly, lung samples were dehydrated 
overnight in 10 mL of 50% v/v tetrahydrofuran/H2O (THF, Sigma 
186562-1L), 50% THF/H2O 1 h, 70% THF/H2O 4 h, 80% THF/H2O 
4 h, 100% THF 1 h, 100% THF overnight, and 100%THF 1 h with 
slightly shaking. Samples were gently dried and then incubated in 
dichloromethane (Sigma 270997-1 L) around 30 min until they sank to 
the bottom. Finally, samples were incubated without shaking in dibenzyl 
ether (DBE, Sigma 108014-1KG) for at least 2 h until imaging and then 
stored in DBE at room temperature.
Lung samples were scanned with an LSFM (Ultramicroscope II, 
LaVision Biotec) equipped with a sCMOS camera (Andor Neo) and 
a 2× objective lens (Olympus MVPLAPO 2×/0.5 numerical aperture 
(NA)) equipped with an Olympus MVX-10 zoom body, which provided 
zoom-out and -in ranging from 0.63× up to 6.3×. For the whole 
lung imaging, light sheet scans were generated with 0.63× zoom 
magnification with individual ex/em bandpass filters for melamine 
NPs (ex/em = 640(30) nm/690(50) nm)and QDs (ex/em = 640(30) 
nm/795(50) nm) with a step size of 10 µm. Tissue autofluorescence 
was imaged under the ex/em = 545(30) nm/605(70) nm filters. Samples 
were typically imaged with an exposure time of 150 ms, at a full laser 
power with the light sheet by adjusting xy width and NA to the sample 
size. High magnification scans (e.g., 8× in Figure 6e,f) were usually 
performed with a step size of 4 µm. The imaging chamber was filled 
with DBE.
Image Processing and Analysis: All (X-ray and CT) images were flat field 
and dark current corrected. X-ray images were analyzed and the dynamic 
NP delivery videos were generated using ImageJ (https://imagej.nih.
gov/ij/). Fluorescence images scanned by IVIS consisting of whole lung 
images and dried lung slices and their corresponding NP dosimetry 
analysis were performed with the Living Imaging 4.0 Software (Caliper). 
The 3D images with maximum intensity projection and videos with 3D 
manipulation scanned by LSFM were processed using Bitplane Imaris. 
All data were presented as mean ± standard deviation and *, **, and 
*** refer to statistically significant differences P < 0.05, P < 0.01, and 
P < 0.001, respectively, and plotted using SigmaPlot version 12.0 (Systat 
Software GmbH, Germany). N ≥ 3.
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